Compare · MTCR vs RGC
MTCR vs RGC
Side-by-side comparison of Metacrine Inc. (MTCR) and Regencell Bioscience Holdings Limited (RGC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MTCR and RGC operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- RGC is the larger of the two at $9.31B, about 427.7x MTCR ($21.8M).
- RGC has hit the wire 2 times in the past 4 weeks while MTCR has been quiet.
- MTCR has more recent analyst coverage (4 ratings vs 0 for RGC).
- Company
- Metacrine Inc.
- Regencell Bioscience Holdings Limited
- Price
- $0.49-0.50%
- $18.25-4.12%
- Market cap
- $21.8M
- $9.31B
- 1M return
- -
- -32.80%
- 1Y return
- -
- -69.58%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2021
- News (4w)
- 0
- 2
- Recent ratings
- 4
- 0
Metacrine Inc.
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with liver and gastrointestinal diseases. It is developing MET409 that has completed Phase 1b proof-of-concept clinical trial for the treatment of patients with non-alcoholic steatohepatitis (NASH); and is in Phase 2a clinical trial in combination with empagliflozin for the treatment of patients with type 2 diabetes mellitus and NASH. The company also develops MET642, which is in Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis patients. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Latest MTCR
- SEC Form 15-12G filed by Metacrine Inc.
- Metacrine Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Leadership Update, Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Klassen Preston
- SEC Form S-8 POS filed by Metacrine Inc.
- SEC Form S-8 POS filed by Metacrine Inc.
- Metacrine Inc. filed SEC Form 8-K: Leadership Update
- Metacrine Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets
- SEC Form EFFECT filed by Metacrine Inc.
- SEC Form 25-NSE filed by Metacrine Inc.
- SEC Form SC 13G/A filed by Metacrine Inc. (Amendment)
Latest RGC
- SEC Form 4 filed by Director Lo William Wing Yan Dr
- SEC Form 4 filed by Director Hui Evana Yee Wah
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 424B5 filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited